Edwards Lifesciences (EW) Profit After Tax (2009 - 2026)

Edwards Lifesciences has reported Profit After Tax for 18 years, with the latest figure at $241.9 million in Q2 2026.

• On a quarterly basis, Profit After Tax fell 27.98% year-over-year to $241.9 million in Q2 2026; TTM through Jun 2026 was $993.3 million, a 76.06% decrease from a year earlier, with the FY2025 full-year figure at $1.1 billion, down 74.28% from the prior year.
• Profit After Tax was $241.9 million for Q2 2026 at Edwards Lifesciences, down from $380.7 million in the prior quarter.
• The five-year high for Profit After Tax was $3.1 billion in Q3 2024, with the low at $77.6 million in Q4 2025.
• Average Profit After Tax over 5 years is $487.9 million, with a median of $360.7 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2025: Profit After Tax jumped 3406.19% in 2022, then sank 90.46% in 2025.
• Over 5 years, Profit After Tax stood at $398.4 million in 2022, then dropped by 7.15% to $369.9 million in 2023, then increased by 4.24% to $385.6 million in 2024, then sank by 79.88% to $77.6 million in 2025, then jumped by 211.73% to $241.9 million in 2026.
• The last three Profit After Tax figures came in at $241.9 million (Q2 2026), $380.7 million (Q1 2026), and $77.6 million (Q4 2025), per Business Quant data.